| scholarly article | Q13442814 |
| P2093 | author name string | Hoang-Xuan T | |
| Morel P | |||
| Bruxelle J | |||
| Chidiac C | |||
| Daures JP | |||
| de Labareyre C | |||
| El Hasnaoui A | |||
| Leplège A | |||
| P2860 | cites work | The MOS 36-ltem Short-Form Health Survey (SF-36) | Q26778425 |
| Validating the SF-36 health survey questionnaire: new outcome measure for primary care | Q35823601 | ||
| Varicella-zoster virus DNA in human sensory ganglia | Q41558362 | ||
| The epidemiology of herpes zoster | Q44454705 | ||
| Quality of life in patients with human immunodeficiency virus infection: impact of social support, coping style and hopelessness | Q45748271 | ||
| The French SF-36 Health Survey: translation, cultural adaptation and preliminary psychometric evaluation | Q47743675 | ||
| Health-related quality of life in chronic disorders: a comparison across studies using the MOS SF-36. | Q51996384 | ||
| Quality of life in migraine and chronic daily headache patients. | Q53560908 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | herpes zoster | Q182155 |
| P304 | page(s) | 62-69 | |
| P577 | publication date | 2001-06-05 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Characteristics of patients with herpes zoster on presentation to practitioners in France | |
| P478 | volume | 33 |
| Q48231410 | 5% lidocaine medicated plaster in elderly patients with postherpetic neuralgia: results of a compassionate use programme in France |
| Q40249121 | Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans |
| Q36015879 | Association of Herpes Zoster and Type 1 Diabetes Mellitus |
| Q36214230 | Awareness, Knowledge, and Vaccine Acceptability of Herpes Zoster in Korea: A Multicenter Survey of 607 Patients |
| Q51155025 | Burden of herpes zoster and postherpetic neuralgia: Incidence, proportion, and associated costs in the French population aged 50 or over |
| Q34468957 | Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study |
| Q33776676 | Burden of post-herpetic neuralgia in a sample of UK residents aged 50 years or older: findings from the Zoster Quality of Life (ZQOL) study |
| Q34461800 | Challenges in quantifying the patient-reported burden of herpes zoster and post-herpetic neuralgia in the UK: learnings from the Zoster Quality of Life (ZQOL) study |
| Q82028956 | Chapter 43 Acute herpes zoster pain |
| Q35916915 | Clinical diagnosis of herpes zoster in family practice |
| Q37190911 | Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older |
| Q34918383 | Consequences and management of pain in herpes zoster |
| Q35065255 | Disease burden of herpes zoster in Sweden--predominance in the elderly and in women - a register based study |
| Q34157441 | Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults |
| Q56768031 | Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom |
| Q35607755 | Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian community of Spain. |
| Q31130703 | Epidemiology and costs of herpes zoster: background data to estimate the impact of vaccination |
| Q34064838 | Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study |
| Q36256539 | Epidemiology of herpes zoster among adults aged 50 and above in Guangdong, China |
| Q33574978 | Epidemiology of herpes zoster infection among patients treated in primary care centres in the Valencian community (Spain). |
| Q26866473 | Evaluation of efficacy and effectiveness of live attenuated zoster vaccine |
| Q38600346 | Functional decline and herpes zoster in older people: an interplay of multiple factors |
| Q35887209 | Herpes zoster and postherpetic neuralgia in Catalonia (Spain) |
| Q37330295 | Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient |
| Q43508371 | Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. |
| Q21261833 | Herpes zoster in Germany: quantifying the burden of disease |
| Q34158156 | Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination |
| Q37346732 | Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis |
| Q48065774 | Herpes zoster-associated severity and duration of pain, health-related quality of life, and healthcare utilization in Taiwan: a prospective observational study |
| Q51153443 | Herpes zoster: Burden of disease in France |
| Q82701478 | Impact of herpes zoster and post-herpetic neuralgia on patients' quality of life: a patient-reported outcomes survey |
| Q42278511 | Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005-2009. |
| Q95658457 | Incidence of herpes zoster among varicella-vaccinated children, by number of vaccine doses and simultaneous administration of measles, mumps, and rubella vaccine |
| Q37670193 | Incidence of herpes zoster in patients with altered immune function |
| Q37057122 | Increased risk of herpes zoster in children with asthma: a population-based case-control study |
| Q36169787 | Increasing incidence associated with herpes zoster infection in British Columbia, Canada |
| Q34092634 | Measuring the burden of herpes zoster and post herpetic neuralgia within primary care in rural Crete, Greece |
| Q34484576 | One-year follow-up of patients with long-lasting post-herpetic neuralgia. |
| Q64097292 | Parameters associated with efficacy of epidural steroid injections in the management of postherpetic neuralgia: the Mayo Clinic experience |
| Q37427315 | Postherpetic neuralgia in the elderly |
| Q36998853 | Postherpetic neuralgia: epidemiology, pathophysiology and management |
| Q40766399 | Pre-Existing Chronic Pain Influences the Severity of Acute Herpes Zoster Pain-A Prospective Observational Cohort Study. |
| Q33714978 | Predictors of pain intensity and persistence in a prospective Italian cohort of patients with herpes zoster: relevance of smoking, trauma and antiviral therapy |
| Q38416454 | Preventing and managing herpes zoster: key actions to foster healthy aging. |
| Q37046161 | Prevention of herpes zoster and its painful and debilitating complications |
| Q36600317 | Prevention of shingles by varicella zoster virus vaccination |
| Q26998625 | Reducing the burden of Herpes Zoster in Italy |
| Q57075974 | Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study |
| Q80445205 | Scientific commentary |
| Q40921109 | Short-term dipeptidyl peptidase-4 inhibitor use increases the risk of herpes zoster infection in Asian patients with diabetes |
| Q26824836 | Similar herpes zoster incidence across Europe: results from a systematic literature review |
| Q47912540 | Single paravertebral injection for acute thoracic herpes zoster: a randomized controlled trial |
| Q39528912 | Skin manifestations of herpesvirus infections |
| Q35887427 | Survey on public awareness, attitudes, and barriers for herpes zoster vaccination in South Korea |
| Q33795551 | Systematic review of incidence and complications of herpes zoster: towards a global perspective. |
| Q50755766 | The consistency of shingles and its significance for health monitoring. |
| Q37141163 | The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine |
| Q31144265 | The epidemiology of varicella disease in Germany after introduction of a vaccination recommendation : Analysis of mandatory and sentinel data between 2002 and 2014 |
| Q35147612 | The humanistic, economic and societal burden of herpes zoster in Europe: a critical review |
| Q33611436 | The impact of herpes zoster and post-herpetic neuralgia on quality-of-life |
| Q34273914 | The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study |
| Q24549730 | The incidence of herpes zoster in a United States administrative database |
| Q21257242 | The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003 |
| Q59100680 | The societal impact of herpes zoster and postherpetic neuralgia on patients, life partners, and children of patients in Germany |
| Q24197622 | Topical lidocaine for the treatment of postherpetic neuralgia |
| Q24245455 | Topical lidocaine for the treatment of postherpetic neuralgia |
| Q24247001 | Topical lidocaine for the treatment of postherpetic neuralgia |
| Q38220158 | Vaccination in the elderly: what can be recommended? |
| Q33454919 | Varicella vaccination in Europe - taking the practical approach |
| Q28111975 | What does epidemiology tell us about risk factors for herpes zoster? |
| Q36992607 | Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine |
| Q36046420 | Zoster duplex: a clinical report and etiologic analysis |
| Q34616238 | Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults |
Search more.